Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study

The combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor and ivacaftor (ETI) has shown a life changing clinical effect in people with cystic fibrosis (pwCF) with at least one phe508del mutation [1 –3]. The use of ETI in pwCF after solid organ transplant is controversial because of potential drug-drug interactions (DDI) with tacrolimus, a first-line immunosuppressive agent and a substrate of CYP3A4 [4]. The inhibition of CYP3A4 and the P-gp inhibition by ivacaftor has a potential risk to inc rease the systemic exposure to tacrolimus [5].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Short Communication Source Type: research